Latest News for: mygn
Edit
Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6%
The Call 05 Aug 2025
MYGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales were flat year on year at $213.1 million ... Myriad Genetics (MYGN) Q2 CY2025 Highlights. ... MYGN) develops genetic tests ...
Edit
Why Myriad Genetics (MYGN) Shares Are Falling Today
The Call 29 Jul 2025
What Happened?. Shares of genetic testing company Myriad Genetics (NASDAQ. MYGN) fell 3.8% in the afternoon session after weakness in the healthcare sector became pronounced following a poor sales report from a key competitor ... More News. View More ... .
Edit
INVESTOR ALERT: Investigation of Myriad Genetics, Inc. (MYGN) Announced by Holzer & Holzer, LLC
Nasdaq Globe Newswire 25 Jun 2025
(“Myriad Genetics” or the “Company”) (NASDAQ. MYGN) complied with federal securities laws ... .
Edit
MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp
The Call 19 May 2025
MYGN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million ... Is now the time to buy MYGN? Find out in our full research report (it’s free). Myriad Genetics (MYGN) Q1 CY2025 Highlights. ... .
- 1